Litcius/Paper detail

Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Danai Dima, James A. Davis, Nausheen Ahmed, Xuefei Jia, Aishwarya Sannareddy, Hira Shaikh, Leyla Shune, Gurbakhash Kaur, Jack Khouri, Aimaz Afrough, Christopher Strouse, Jonathan Lochner, Zahra Mahmoudjafari, Shahzad Raza, Jason Valent, Larry D. Anderson, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi

2023Transplantation and Cellular Therapy78 citationsDOI

Topics & Concepts

MedicineInternal medicineRefractory (planetary science)Multiple myelomaCytokine release syndromePopulationClinical trialProgression-free survivalSalvage therapyGastroenterologyOncologySurgeryOverall survivalChemotherapyImmunotherapyCancerChimeric antigen receptorEnvironmental healthPhysicsAstrobiologyMultiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisProtein Degradation and Inhibitors
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience | Litcius